Cynthia Collins
CIK 1405692 · CEO · last filed 2026-05-15
Cynthia Collins is a CEO who has filed 79 SEC Form 4 insider transactions across 8 companies since 2008. The most recent filing, for CERT, was dated May 15, 2026. Across all open-market trades the lifetime net is −$299.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $738.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$738.8K
8
79
-$299.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CERT | Director | 51,846 | $5.20 | $269.6K | $0 | 7 | 2026-05-15 |
| MXCT | Director | 80,889 | $1.12 | $90.6K | $0 | 2 | 2025-06-23 |
| CDXS | Director | 112,157 | $2.40 | $269.2K | $0 | 2 | 2025-06-12 |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 5 | 2025-01-08 |
| DermTech, Inc. (DMTK) Delisted | Director | 104,835 | $0.09 | $9.9K | $0 | 6 | 2023-06-05 |
| EDIT | CEO | 43,760 | $2.50 | $109.4K | -$290.7K | 9 | 2021-02-10 |
| GENVEC INC (GNVC) Delisted | President & CEO | — | — | — | $0 | 2 | 2013-01-24 |
| BECKMAN COULTER INC (BEC) Delisted | Group Vice President | 10,665 | — | — | -$8.7K | 45 | 2011-06-28 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-15 | CERT | Exer (M) | +15,757 | $0 | EDGAR |
| 2025-06-23 | MXCT | Grant (A) | +29,210 | $0 | EDGAR |
| 2025-06-12 | CDXS | Grant (A) | +40,983 | $0 | EDGAR |
| 2025-05-22 | CERT | Mixed | +11,928 | $0 | EDGAR |
| 2025-04-01 | CDXS | Grant (A) | +71,174 | $0 | EDGAR |
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −58,950 | $0 | EDGAR |
| 2024-10-16 | MXCT | Grant (A) | +51,679 | $0 | EDGAR |
| 2024-06-18 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +19,650 | $0 | EDGAR |
| 2024-05-23 | CERT | Mixed | +8,663 | $0 | EDGAR |
| 2023-06-16 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +19,650 | $0 | EDGAR |